Cogent Biosciences Stock 346% Surge Fueled by New Stake
A Phase 3 breakthrough unleashed a dramatic move in Cogent Biosciences. A large fund followed with a sizable stake, s...
This piece identifies funds with the highest management charges in the Dividend Aristocrats group and explains potential impact on performance.
26,423 articlesA Phase 3 breakthrough unleashed a dramatic move in Cogent Biosciences. A large fund followed with a sizable stake, s...
A major institutional move signals a shift in risk tolerance and strategy. Learn what arcus capital scales back means...
The allure of in-person auditions can draw massive crowds—and big financial and safety risks. Cenat’s streamer univer...
When private materials move from a safe shelf to a digital vault, money and privacy collide. This article examines hu...
AMD’s latest earnings call highlights a rapid AI-led growth wave and a massive server CPU opportunity. Here are the f...
Markets brace for a potential rate move at the July FOMC meeting as JPMorgan Asset Management weighs in on Warsh-era ...
A major stake sale in Arcellx coincides with fresh competition in the field. This analysis breaks down what happened,...
Investors piled into Nextpower after strong 2026 results and a strategic acquisition. This article breaks down the ca...
A sweeping update from Fannie Mae and Freddie Mac is redefining how condos are financed, insured, and funded. The pol...
Synopsys topped earnings and revenue expectations as AI-fueled chip design demand remains strong. Yet softer Q2 guida...
Could Ethereum reach $5,000 by 2030? This article breaks down the logic, the timing, and practical steps you can take...
The ADA conference spotlighted Lilly and Novo Nordisk in the GLP-1 race. This deep dive explains what the claims mean...